

IN THE SPECIFICATION:

Please disregard the reply filed on 5/14/01 (paper #20).

Please disregard the statement "On Page 10, lines 11 and 12, please delete [R]" in the previous amendment (filed 11/18/00), and instead, please amend as follows:

On page 11, lines 10-12, please delete [R]. The new paragraph should read:

31 In one embodiment, the prosaposin receptor agonist useful in the invention is a prosaposin receptor agonist of 14 to 50 amino acids which has the amino acid sequence LIRX₁NNX₂T X₃ X₄ X₃ X₁ X₁, where X₁ is any amino acid; X₂ is any amino acid, but not L or R; X₃ is a charged amino acid; and X₄, when present, is a charged amino acid.

IN THE CLAIMS:

Please amend claim 4 as follows and substitute it for the previously amended (reply filed 11/18/00) claim 4.

4. (Twice amended) A pharmaceutical composition for treating neuropathic pain, comprising:

[the]a prosaposin receptor agonist consisting of the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in an effective amount that is greater than 20 µg/kg and less than 100 µg/kg of body weight; and
a pharmaceutically acceptable carrier.

The amended claim should be:

32 4. A pharmaceutical composition for treating neuropathic pain, comprising:
a prosaposin receptor agonist consisting of the sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 in an effective amount that is greater than 20 µg/kg and less than 100 µg/kg of body weight; and
a pharmaceutically acceptable carrier.